期刊文献+

血清甲状旁腺素和降钙素水平对骨代谢影响的临床研究 被引量:1

下载PDF
导出
摘要 骨质疏松症(osteoporosis,OP)是一种以骨量降低、骨组织微结构破坏、骨脆性增加及易发生骨折为特征的全身性代谢性疾病。2001年由美国国立卫生研究院(NIH)提出OP的定义为以骨强度下降和骨折风险增加为特征的骨骼系统疾病,骨强度反映骨骼的2个方面,即骨质量及骨矿密度。根据世界卫生组织(WHO)分类,OP有3种类型,包括原发性OP、继发性OP和特发性OP。
作者 李朦 袁耿彪
出处 《现代医药卫生》 2013年第15期2308-2310,共3页 Journal of Modern Medicine & Health
  • 相关文献

参考文献27

  • 1中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011 年)[EB/OL]. [2011-12-29]. http://www.haodf.com/zhuanjiaguandian/liaodefa_583581080.htm.
  • 2中华医学会.临床诊疗指南骨质疏松症和骨矿盐疾病分册[M].北京:人民卫生出版社,2006:2-3.
  • 3Zhu H,Fang J,Luo X,et al. A survey of bone mineral density ofhealthy Han adults in China [J]. Osteoporosis Int, 2010,21 (5):765-772.
  • 4李宁华,朱汉民,区品中,杨定焯,郑苹如.中国部分地区中老年人群原发性骨质疏松症患病率研究[J].中华骨科杂志,2001,21(5):275-278. 被引量:188
  • 5郭慧峰,张省亮,潘锋丰,张华,钟远.骨代谢标志物与老年骨质疏松症的相关性[J].中国医药导刊,2011,13(10):1710-1710. 被引量:26
  • 6Glover SJ,Gall M,Schoenbom-Kellenberger O, et al. Establishinga reference interval for bone turnover markers in 637 healthy,young, premenopausal women from the United Kingdom, France,Belgium, and the United States [J]. J Bone Miner Res, 2009,24(3):389-397.
  • 7何郁泉,潘子昂,刘京萍,王石麟,刘忠厚.男性骨质疏松[J].中国骨质疏松杂志,1995,1(1):63-66. 被引量:35
  • 8朱汉民,程群,甘洁民,杜艳萍,洪维,朱晓颖,李慧林.上海地区人群维生素D状态研究[J].中华骨质疏松和骨矿盐疾病杂志,2010,3(3):157-163. 被引量:135
  • 9Jesudason D,Need AG,Horowitz M,et al. Relationship betweenserum 25 -hydroxyvitamin D and bone resorption markers in vi-tamin D insufficiency[J]. Bone,2002,31 (5): 626-630.
  • 10Durazo-Arvizu RA,Dawson-Hughes B,Sempos CT,et al. Three-phase model harmonizes estimates of the maximal suppression ofparathyroid hormone by 25-hydroxyvitamin D in persons 65 yearsof age and older[J]. J Nutr,2010,140(3) :595-599.

二级参考文献101

共引文献441

同被引文献40

  • 1单春艳,郑少雄,陈莉明,J Y Reginster.绝经后骨质疏松妇女全血细胞分泌某些细胞因子水平的改变[J].中国组织工程研究与临床康复,2001,10(18):104-105. 被引量:7
  • 2Reid IR,Mason B,Home A,et al. Randomized controlled trial of calci-um in healthy older women[ J]. Am J Med,2006,119(9) :777 -785.
  • 3Larsen E R, Mosekilde L, Foldspang A, et al. Vitamin D and calciumsupplementation prevents osteoporotic fractures in elderly communitydwelling residents: a pragmatic population - based 3 - year interventionstudy[ J]. J Bone Miner Res,2004,19(3) :370 -378.
  • 4Baron R. Osteoporosis in 2011 : Osteoporosis therapy - dawn of the post-bisphosphonate era[ J]. Nat Rev Endocrinol ,2011,8 : 76-78.
  • 5Modi N D,Lentzsch S. Bisphosphonates as antimyeloma drugs[ J]. Leu-kemia,2012,26(4) :589 - 594.
  • 6Siddiqi A, Payne A G, Zafar S. Bisphosphonate - induced osteonecrosisof the jaw: a medical enigma. [J]. Oral Surg Oral Med Oral PatholOral Radiol Endod, 2009,108(3) : el - 8.
  • 7Li Y F, Zhou C C,Li JH al. The effects of combined human parathy-roid hormone (1 - 34 ) and zoledronic acid treatment on fracture healingin osteoporotic rats[ J]. Osteoporos Int,2012,23(4) :1463 - 1474.
  • 8Pantano F, Zoccoli A, Iuliani Mfet al. New targets, new drugs for meta-static bone pain:a new Philosophy[ J]. Emerging Drugs,2011,16(3):403.
  • 9Henry D H,Costa L,Goldwasser F, et al. Randomized,double - blindstudy of denosumab versus zoledronic acid in the treatment of bone me-tastases in patients with advanced cancer ( excluding breast and prostatecancer) or multiple myeloma[ J]. J Clin Oncol,2011,29(9) :1125.
  • 10Martin T,Gooi J H,Sims N A. Molecular mechanisms in coupling ofbone formation to resorption[ J]. Crit Rev Eukaryot Gene Expr,2009 ,19(1) : 73 -88.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部